Immunovant, Inc.

Roivant’s confidence in Immunovant’s neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402 has only grown, Roivant CEO Matt Gline said, since the company and its subsidiary announced ea

Biohaven has provided mixed updates from its broad and ambitious pipeline, with solid but unspectacular results from its protein degrader candidate, BHV-1300, and a miss from its ion channel activator

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/I